Incyte (INCY) Sell-Off on Opzelura Miss an 'Overreaction' - Truist
Tweet Send to a Friend
Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $95.00 price target on Incyte (NASDAQ: INCY), saying the stock ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


